Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development and commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. The firm products include rHuPH20, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

HALO reports 38% YoY revenue growth, faces patent challenge

HALO reported strong Q1 2023 performance with significant revenue growth and completion of a share buyback program. However, challenges arise from the revocation of a European co-formulation patent for DARZALEX. Despite this, HALO remains confident in future revenues and royalties, with opportunities in new launches and ENHANZE investments.

Halozyme reports record Q2 revenues and projects substantial growth

Halozyme's Q2 2023 earnings call showcased strong financial performance, with record revenues and substantial revenue growth projections. The company's focus on advancing and expanding the product portfolio, along with the expectation of long-term royalty revenues, reflects a commitment to innovation and stability. However, challenges related to market dynamics, potential partners, and varying product uptake speeds present areas of uncertainty. Despite these challenges, opportunities for new revenue streams and expansion through partnerships and product approvals are evident.

Halozyme reports robust Q3 earnings, eyes market share growth

Halozyme's Q3 2023 earnings call showcased strong financial and operational performance, with raised guidance and a focus on capital allocation. The company faces the challenge of capturing market share in a dominated market and uncertainty around potential approval dates. However, opportunities lie in the potential uptake of new products and expansion of partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q2 2020 Results - Earnings Call Transcript

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -24.00% and -20.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Lag Estimates

SAN DIEGO, Aug. 10, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme Reports Significant Recent Achievements And Second Quarter 2020 Results

Amicus Therapeutics

Intercept Pharma

Novavax

Reata Pharmaceuticals

Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.

Biotech Stock Q2 Earnings on Aug 10: NVAX, ICPT & More

SAN DIEGO, Aug. 4, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Halozyme To Present At Canaccord Genuity 40th Annual Growth Conference

Halozyme Therapeutics: Enhanced Prospects, Expensive Valuations

A bull signal is flashing for Halozyme Therapeutics (HALO), which just came off a record peak

Biotech Shines Bright While Bull Signal Flashes

SAN DIEGO, June 29, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved Roche's Phesgo™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, a fixed-dose combination (FDC) of Perjeta® and...

Halozyme Announces Roche Receives FDA Approval For Phesgo™ (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast Cancer

Halozyme Therapeutics (HALO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Halozyme Therapeutics (HALO) Stock Might be a Great Pick

SAN DIEGO, June 17, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will be participating in the upcoming BMO 2020 Prescriptions for Success Healthcare Conference, which is being held as a...

Halozyme To Participate In The BMO 2020 Prescriptions For Success Healthcare Conference

SAN DIEGO, June 13, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Research & Development, LLC (Janssen) presented data from its Phase III ANDROMEDA (AMY3001) study of subcutaneous (SC) daratumumab utilizing ENHANZE® in combination with...

Halozyme Announces Findings From Janssen's Phase 3 Andromeda Study Evaluating Subcutaneous Daratumumab Utilizing ENHANZE® In Light-Chain Amyloidosis Presented At European Hematology Association 25th Annual Congress

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?

Why Is Halozyme Therapeutics (HALO) Up 1% Since Last Earnings Report?

SAN DIEGO, June 4, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission (EC) has granted Janssen-Cilag International NV (Janssen) marketing authorization for the subcutaneous (SC) formulation of DARZALEX® (daratumumab), for the...

Halozyme Announces Janssen Receives European Marketing Authorization For Subcutaneous DARZALEX® Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma

SAN DIEGO, May 28, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will be participating in the following investor conferences: Jefferies Virtual Healthcare Conference at 10:00 a.m. ET / 7:00 a.m....

Halozyme To Present At Upcoming Virtual Investor Conferences

Halozyme (HALO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Why Halozyme (HALO) Could Be Positioned for a Surge

Halozyme (HALO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Halozyme (HALO) Stock Might be a Great Pick

II-VI Incorporated

Kopin

MEI Pharma

Top Ranked Momentum Stocks to Buy for May 15th

SAN DIEGO, May, 14, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the company will receive a $15 million milestone payment from Janssen Biotech, Inc. (Janssen) triggered under the Collaboration and License Agreement between the two companies. The...

Halozyme To Receive $15 Million Milestone Payment From Janssen

Halozyme (HALO) reports wider-than-expected Q1 loss. Shares down.

Halozyme (HALO) Q1 Earnings and Revenues Miss Estimates

Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q1 2020 Results - Earnings Call Transcript

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -300.00% and -35.57%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics (HALO) Reports Q1 Loss, Lags Revenue Estimates

As of late, it has definitely been a great time to be an investor Halozyme Therapeutics

News for Halozyme Therapeutics Stock (HALO)